Divi's Laboratories revenue and financials
₹9,550.00Change from previous close: +3.85%Absolute change: +₹354.00
In the fiscal year ended March 2026, Divi's Laboratories reported revenue of ₹104.76B (+12.34% year over year). Net income was ₹25.68B, a net margin of 24.5%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +12.34%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +17.21%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 24.5%
- FY to Mar 2025: 23.5%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total assets | 200,330 | 169,320 | 154,700 | 144,390 | — |
| Current assets | 110,960 | 100,810 | 96,750 | 93,120 | — |
| Cash and equivalents | 1,280 | 4,150 | 3,630 | 1,700 | — |
| Short-term investments | 31,080 | 31,240 | 33,380 | 39,660 | — |
| Inventory | 39,540 | 32,360 | 31,840 | 30,000 | — |
| Net property, plant and equipment | 87,690 | 66,980 | 56,320 | 49,480 | — |
| Other intangible assets | 60.0 | 40.0 | 40.0 | 50.0 | — |
| Current liabilities | 20,430 | 14,520 | 12,780 | 11,010 | — |
| Accounts payable | 12,110 | 9,100 | 8,240 | 7,620 | — |
| Total debt | 70.0 | 40.0 | 30.0 | 40.0 | — |
| Total liabilities | 32,720 | 19,630 | 18,990 | 16,720 | — |
| Total equity (incl. minority) | 167,610 | 149,690 | 135,710 | 127,670 | — |
| Retained earnings | 153,700 | 134,000 | 117,860 | 109,590 | — |